Leukemias, lymphomas, and other hematologic cancers:

Indications for: VONJO

Treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50×109/L.

Adult Dosage:

Swallow whole. 200mg twice daily. Dose modification for adverse reactions: see full labeling.

Children Dosage:

Not established.

VONJO Contraindications:

Concomitant with strong CYP3A4 inhibitors (eg, clarithromycin) or inducers (eg, rifampin).

VONJO Warnings/Precautions:

Risk for hemorrhage. Avoid use in those with active bleeding. Discontinue treatment 7 days prior to elective surgery or invasive procedures; restart only after hemostasis is assured. Control preexisting diarrhea prior to initiation. Interrupt or reduce dose if significant diarrhea occurs despite optimal supportive care. Preexisting moderate to severe thrombocytopenia. Interrupt treatment if clinically significant worsening of thrombocytopenia develops lasting for more than 7 days. Risk for prolonged QT interval; avoid use if baseline QTc >480msec. Correct hypokalemia prior to and during treatment. Perform CBCs (including WBC differential, platelets), coagulation testing, baseline ECG prior to initiation and monitor as indicated during therapy. Increased risk for MACE, thrombosis, lymphoma, and other malignancies; monitor. Consider the risks/benefits esp. in patients with known malignancy, cardiovascular risk factors, or current/past smokers. Increased risk of serious infections (eg, bacterial, mycobacterial, fungal, or viral); delay starting therapy until active serious infections have resolved. Monitor for infection during treatment. Renal impairment (eGFR <30mL/min), moderate or severe hepatic impairment: avoid. Pregnancy. Nursing mothers: not recommended (during and for 2 weeks after the last dose).

VONJO Classification:

Kinase inhibitor.

VONJO Interactions:

See Contraindications. Avoid concomitant drugs with significant potential for QTc prolongation. Potentiated by moderate CYP3A4 inhibitors; avoid. Antagonized by moderate CYP3A4 inducers; avoid. Potentiates sensitive substrates of CYP1A2, CYP3A4, P-gp, BCRP, or OCTI; avoid.

Adverse Reactions:

Diarrhea, thrombocytopenia, nausea, anemia, peripheral anemia, vomiting, dizziness, pyrexia, epistaxis, dyspnea, pruritus, upper RTI, cough; serious cardiovascular events.


CYP3A4. ~98.8% plasma protein bound.

Drug Elimination:

Fecal (87%), renal (6%). Half-life: 27.7 hours.

Generic Drug Availability:


How Supplied: